Barinthus Biotherapeutics (NASDAQ:BRNS) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Posted by Brenda Bartman on Aug 7th, 2026

Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) announced its earnings results on Thursday. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02, FiscalAI reports.

Barinthus Biotherapeutics Stock Performance

Shares of Barinthus Biotherapeutics stock traded up $0.03 on Friday, hitting $0.60. 34,881 shares of the company traded hands, compared to its average volume of 40,767. Barinthus Biotherapeutics has a 52 week low of $0.51 and a 52 week high of $1.83. The business has a 50-day simple moving average of $0.64 and a 200 day simple moving average of $0.64. The stock has a market capitalization of $24.47 million, a P/E ratio of -0.58 and a beta of -0.39.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $4.00.

View Our Latest Stock Report on Barinthus Biotherapeutics

Institutional Trading of Barinthus Biotherapeutics

An institutional investor recently raised its position in Barinthus Biotherapeutics stock. Renaissance Technologies LLC grew its position in shares of Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS – Free Report) by 115.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 143,100 shares of the company’s stock after purchasing an additional 76,800 shares during the period. Renaissance Technologies LLC owned approximately 0.35% of Barinthus Biotherapeutics worth $100,000 at the end of the most recent reporting period. 25.20% of the stock is owned by institutional investors and hedge funds.

Barinthus Biotherapeutics Company Profile

(Get Free Report)

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.